Financials
Financial year 2025
Pharmagrex from Boom, company number BE0635846678, closed financial year 2025 with a result of € 284,105 after tax. For that financial year Pharmagrex recorded a gross margin of € 399,874 and equity of € 1.3 million. Compared with financial year 2024, the result moved from € 201,707 to € 284,105. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 23, 2026.
€ 1.3 million
▲ 20% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 284,105
▲ 41% vs 2024
Profit after tax over the fiscal year.
€ 33,968
▲ € 29,487 vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 65,000 paid out
23 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 10,217
Supplier invoices still open on the last day of the fiscal year.
€ 179,347
▲ 84% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 33,770 | € 12,532 | € 319,567 | € 399,874 | ▲ 25% |
| Profit after taxes | € 187,306 | € 1,457 | € 201,707 | € 284,105 | ▲ 41% |
| Equity | € 960,213 | € 961,670 | € 1,088,377 | € 1,307,483 | ▲ 20% |
| Total debts | € 235,489 | € 196,698 | € 249,860 | € 189,563 | ▼ 24% |
| Cash | € 4,883 | € 3,205 | € 4,481 | € 33,968 | ▲ € 29,487 |
| Retained profit | € 760,213 | € 761,670 | € 888,377 | € 1,107,483 | ▲ 25% |
| Dividend | € 0 | € 0 | € 75,000 | € 65,000 | ▼ 13% |
| Bank debt | € 205,285 | € 131,815 | € 50,708 | € 0 | ▼ 100% |
| Balance sheet total | € 1,195,703 | € 1,158,368 | € 1,338,238 | € 1,497,046 | ▲ 12% |
Key figures of Pharmagrex, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Pharmagrex?
What happened at Pharmagrex in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 284,105 (▲ 41% vs 2024). filed late Source: NBB ↗
- Bénédicte De Groof became a director. NBB
- Alexander De Groof became a director. NBB
- New establishment in Boom. KBO
- Martine Bleys became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 187,306 profit in 2022 to € 284,105 profit in 2025.
Paid € 259,258 in corporate taxes since 2022.
Best year ever: 2025, with € 284,105 profit.
Paid out € 140,000 in dividends to the owners in total.
Management
Behind Pharmagrex are Bénédicte De Groof, Alexander De Groof and Martine Bleys.
Directors
According to the 2025 annual accounts
Bénédicte De Groof
Director
since 2020
Alexander De Groof
Director
since 2020
Martine Bleys
Director
since 2015
Establishments
Establishment units
Physical locations of this company
Peter Benoitstraat 46
2850 Boom
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0635.846.678
- VAT number
- BE 0635.846.678
- Registered office
- Peter Benoitstraat 46, 2850 Boom
- Names & denominations
- Pharmagrex
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 August 2015
- Peppol
- Active · Active since 15 Jul 2026
- Activities · NACE
Activiteiten van holdings
Holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering